WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 200230
CAS#: 861998-00-7 (HCl)
Description: Anamorelin, also known as RC-1291 or ONO-7643, is the orally bioavailable, small-molecule ghrelin mimetic with appetite-stimulating and anabolic activities. Anamorelin binds to and stimulates the growth hormone secretagogue receptor (GHSR) centrally, thereby mimicking the appetite-stimulating and growth hormone-releasing effects of grhelin. Stimulation of GHSR may also reduce the production of the pro-inflammatory cytokines TNF-alpha and interleukin-6, which may play a direct role in cancer-related loss of appetite.
MedKoo Cat#: 200230
Name: Anamorelin HCl
CAS#: 861998-00-7 (HCl)
Chemical Formula: C31H43ClN6O3
Exact Mass:
Molecular Weight: 583.16
Elemental Analysis: C, 63.85; H, 7.43; Cl, 6.08; N, 14.41; O, 8.23
Related CAS #: 861998-00-7 (HCl) 249921-19-5 (free base)
Synonym: RC 1291; RC1291; RC-1291; RC 1291HCl; ONO7643; ONO-7643; ONO 7643; Anamorelin HCl
IUPAC/Chemical Name: 2-amino-N-((R)-1-((R)-3-benzyl-3-(1,2,2-trimethylhydrazinecarbonyl)piperidin-1-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-2-methylpropanamide hydrochloride
InChi Key: VFYAEUWJFGTGGO-GHTUPXNNSA-N
InChi Code: InChI=1S/C31H42N6O3.ClH/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22;/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39);1H/t26-,31-;/m1./s1
SMILES Code: CC(C)(N)C(N[C@H](CC1=CNC2=C1C=CC=C2)C(N3C[C@](C(N(C)N(C)C)=O)(CC4=CC=CC=C4)CCC3)=O)=O.[H]Cl.
Appearance: white to off-white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in water or buffer.
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 583.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Zhang H, Garcia JM. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opin Pharmacother. 2015 Jun;16(8):1245-53. doi: 10.1517/14656566.2015.1041500. Epub 2015 May 6. PubMed PMID: 25945893.
2: von Haehling S, Anker SD. Treatment of cachexia: An overview of recent developments. Int J Cardiol. 2015 Apr 1;184:736-42. doi: 10.1016/j.ijcard.2014.10.026. Epub 2014 Oct 16. PubMed PMID: 25804188.
3: Baracos VE. Skeletal muscle anabolism in patients with advanced cancer. Lancet Oncol. 2015 Jan;16(1):13-4. doi: 10.1016/S1470-2045(14)71185-4. Epub 2014 Dec 16. PubMed PMID: 25524803.
4: Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015 Jan;16(1):108-16. doi: 10.1016/S1470-2045(14)71154-4. Epub 2014 Dec 16. PubMed PMID: 25524795.
5: von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. J Am Med Dir Assoc. 2014 Dec;15(12):866-72. doi: 10.1016/j.jamda.2014.09.007. Epub 2014 Nov 20. PubMed PMID: 25455531.
6: von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):261-3. doi: 10.1007/s13539-014-0164-8. PubMed PMID: 25384990; PubMed Central PMCID: PMC4248411.
7: Salsman JM, Beaumont JL, Wortman K, Yan Y, Friend J, Cella D. Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia. Support Care Cancer. 2015 May;23(5):1355-64. doi: 10.1007/s00520-014-2484-9. Epub 2014 Oct 29. PubMed PMID: 25351456; PubMed Central PMCID: PMC4376952.
8: Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Yuanfeng X, Duus EM, Northrup R. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):329-37. doi: 10.1007/s13539-014-0159-5. Epub 2014 Sep 30. PubMed PMID: 25267366; PubMed Central PMCID: PMC4248409.
9: Ebner N, Steinbeck L, Doehner W, Anker SD, von Haehling S. Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies. J Cachexia Sarcopenia Muscle. 2014 Mar;5(1):27-34. doi: 10.1007/s13539-014-0136-z. Epub 2014 Mar 5. PubMed PMID: 24595460; PubMed Central PMCID: PMC3953317.
10: Currow DC, Abernethy AP. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncol. 2014 Apr;10(5):789-802. doi: 10.2217/fon.14.14. Epub 2014 Jan 28. PubMed PMID: 24472001.
Related:
861998-00-7 (Anamorelin HCl salt)
249921-19-5 (Anamorelin free base)
